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Abstract
Bone is an active tissue that works as a tissue and an organ as well. It is 
 constituted of cells and blood vessels by nearly 10% of its volume, while the rest 
90% is majorly contributed by extracellular portion. Bone is a living structure 
stably undertaking continual remodeling between bone formation and bone 
resorption, where bone-forming cells (osteoblasts) and bone-resorbing cells 
(osteoclasts) exhibit a crucial role. The differentiation process of osteoblasts 
and osteoclasts takes place in a balanced manner under normal conditions. This 
intricate balance is chiefly sustained by biochemical signaling cascades, facilitat-
ing accurate bone homeostasis in the body. Loss of balance/misregulated signal-
ing in the bone development or disruption may lead to pathological conditions 
such as osteoporosis, arthritis, etc. Among several regulators for bone-signaling 
pathways, microRNAs have appeared as an imperative control of gene expres-
sion at the level of post-transcription while addressing the genes that control 
bone remodeling with appropriate responses in the pathogenesis and perhaps the 
management of bone diseases. Further, microRNAs control the proliferation and 
differentiation of osteoblasts and osteoclasts, which finally influence the bone 
formation. Hence, there is a great possibility in exploiting microRNAs as putative 
therapeutic targets for the medical relief of bone associated disorders, including 
osteoporosis.
Keywords: bone formation, signaling pathways, osteoporosis, microRNAs, 
therapeutics
1. Introduction
Bone is a tough and dynamic tissue that provides shape to our body while 
protecting the organs [1]. Bone formation is chiefly regulated by the precise 
biochemical signaling pathways that maintain the action of the bone cells viz. 
osteoblasts and osteoclasts [2]. These bone cells act in a balanced and stable 
fashion in the normal functioning of the bone. Disruptions in this intricate 
balance results in absurd bone functions with the consequent occurrence of bone 
associated disorders. Osteoporosis is one such well-recognized bone disease that 
is patented by the decreased bone mineral density and loss of connectivity in the 
bone trabeculae [3]. Osteoporosis has been documented to elicit approximately 
8.9 million fractures annually, targeting around 200 million osteoporotic women 
across the globe [4, 5]. As per the International Osteoporosis Foundation, osteopo-
rosis results in 1.5 million fractures per year in the USA while in Europe, more than 
3.5 million osteoporotic fractures have been reported each year [6, 7]. Besides, in 
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India approximately 61 million people are stated as diseased osteoporotic patients 
[8, 9]. Therefore, management of osteoporosis is the urgent need of the hour for 
providing relief to the masses and hence refining the quality of life. Apart from 
numerous therapeutic measures available for the treatment, osteoporosis is still 
largely undertreated and seeks improved strategies that are associated with fewer 
side effects.
MicroRNA (miRNA) antagonism might be a new therapeutic approach for 
the check of osteoporosis. miRNAs are small RNAs (21–23 nucleotides) that act 
as post-transcriptional regulators of gene expression [10]. In a broader sense, 
miRNAs execute their functions either by degrading the gene (mRNAs) or by 
repressing the translation of the protein for the respective gene [11]. miRNA 
mediated targeting of expression for the genes that are involved in bone remodel-
ing and regeneration is a novel and specific mode of therapeutic strategy. Various 
miRNAs control the proliferation and differentiation potential of osteoblasts and 
osteoclasts that ultimately regulates the bone formation [12]. There are numer-
ous studies that report the prominence of miRNA functions and miRNA-based 
antagonism in the maintenance of bone homeostasis [13]. While acting on the 
mRNAs, miRNAs can stimulate as well inhibit the activity of osteoblasts and 
osteoclasts in the bone remodeling [14]. miRNAs are able to obstruct the exces-
sive bone loss during osteoporosis and encourages the bone formation [15]. In 
short, miRNAs are anticipated to serve as putative gene therapy targets for the 
treatment of bone-related injuries [16]. Hence the present chapter details the role 
and efficacy of miRNA in the management of osteoporosis. Finally, we describe 
the mechanism by which miRNAs can regulate the gene expression in bone 
formation and resorption.
2. Bone
Bone is an active connective tissue that behaves like an organ as well [1]. 
The most fundamental function of the bone is to offer support and shape to the 
body [17]. Other than that, bone also serves endocrine functions and assists in 
hematopoiesis [18]. Broadly, the structure of bone is categorized into two types, 
namely cancellous or cortical bone. Cortical/compact type comprises of 80% of 
the bone skeleton, whereas cancellous/spongy makes up to 20% [19]. Cortical 
bone forms the dense outer linings of the strong bones, and spongy bone is pres-
ent at the ends of the long bones [20]. Bone is associated with dynamic character 
and undertakes continual remodeling, wherein the aged bone is resorbed, and 
new bone is continually ossified [21]. The bone resorptive episode takes around 
10 days to complete, whereas the formation of bone persists for a period of 3 
months [22].
2.1 Components of bone
Two vital components of the bone composition are matrix and cells [23]. 
Matrix is further consists of organic part (30%) and inorganic part/ minerals 
(70%) [23]. Around 90% of the bone organic matrix is made of collagen type 1 
and rest 10% includes proteins such as osteocalcin, osteopontin, osteonectin, etc. 
[19]. In addition, bone is a storehouse for minerals, especially calcium and phos-
phorous, that makes the hydroxyapatite element of the bone. Hydroxyapatite 
provides framework and strength to the bone. Furthermore, bone is comprised 
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of four basic cell types, viz. osteoblasts, osteoclasts, osteocytes and bone lin-
ing cells [24]. Osteoblasts are bone-forming cells that arise from mesenchymal 
stem cells. Several growth (FGF) and transcription factors (Runx2, Osterix) 
are responsible for the differentiation of mesenchymal cells to the osteoblastic 
lineage [25]. Osteoclasts are bone-resorbing cells that originate from hematopoi-
etic monocyte-macrophage lineage, which differentiates via the assistance of the 
receptor activator of nuclear factor-κB ligand (RANK ligand) and Macrophage 
colony-stimulating factor (M-CSF) [26]. Osteoclasts are the biggest (in size) 
of all other cell types of the bone. Osteocytes constitute 95% of the cells in the 
mature skeleton [1]. These are the mineralized differentiated osteoblast cells that 
regulate the process of bone remodeling. Bone lining cells are a type of flat osteo-
blastic cells that sheet the quiescent bone surfaces [27]. They favor to safeguard 
the bone, maintain the bone fluids and form a barrier between the bone and bone 
marrow.
3. Physiological bone regeneration
Bone modeling is a specialized process wherein old bones are removed 
from one location and replaced by new bone at a distinct location. This process 
defines the ultimate shape and size of the skeleton [28]. While bone remodel-
ing is a characteristic process in the mature skeleton that is marked by constant 
bone restoration via a frequent exchange of aged bone with the fresh one at 
the same site. The process results in the comprehensive regeneration of mature 
skeleton in an adult every 10 years [29]. The body tries to sustain the balance 
between bone formation and elimination during the process of bone remodel-
ing. It takes place in discrete sites called basic multicellular units (BMU). The 
process initiates by activation phase where an initiating signal (e.g., mechanical 
strain on the bone, fracture healing, etc.) flags the requirement of the remodel-
ing process [30]. After the activation, the commencement of the resorptive 
phase occurs, wherein osteoclasts depletes bone by proteolytic degradation and 
acidification. Osteoblasts travel to the eroded space and begin the ossification 
after the stimulation of transcription factors that encourages the bone forma-
tion [31]. Ossified bone is subsequently mineralized and eventually remodeling 
cycle ends.
4. Biochemical signaling pathways that regulate the bone formation
Bone formation is controlled by numerous elements including transcription 
factors, hormones, growth factors, oxidative processes, mechanical loading, stress, 
bone fractures and aging [32]. Osteoblasts and osteoclasts are able to read these 
external stimulants and propagate the biochemical signals via various signaling 
cascades. The biological response of the selected signaling pathways results either 
in bone formation or disruption. Some of the crucial pathways operating in the 
osteoblasts and osteoclasts are described as follows:
4.1 Wnt/β-catenin pathway
The Wnt signaling pathway has an enormous vital role in the bone development 
and maintenance of bone homeostasis [33]. Wnt is a secreted protein ligand that 
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binds to a receptor complex of Frizzled (Fz) and low-density lipoprotein receptor-
related proteins (LRP). There are two modes of functioning for the Wnt proteins, i.e., 
canonical and non-canonical pathways, wherein the canonical pathway has a more 
specific role to play in the bone development. In the canonical pathway (Figure 1), 
the interaction of Wnt to the receptor complex hinders the functioning of axin, gly-
cogen synthase kinase 3β (GSK-3β) and adenomatous polyposis coli (APC) protein. 
This primes the accumulation of β-catenin in the cytoplasm, further β-catenin travels 
down to the nucleus and ultimately stimulates lymphoid-enhancer-binding factor/T-
cell-specific transcription factors (LEF/TCF). This results in the transcriptional 
activation for the genes that participate in bone formation and regeneration. While 
the absence of Wnt signal leads to phosphoryla tion of the cytosolic β-catenin and its 
subsequent ubiquitin-mediated degradation [34]. The degradation of the β-catenin 
finally turns off the downstream activation of the osteogenic genes. Accurate Wnt 
signaling is a pre-requisite for adequate bone mass in the body while mutation of the 
Wnt signaling components results in fractures and bone injuries [35].
4.2 BMP-Smad pathway
Bone morphogenetic protein (BMP) holds a well-known and fundamental role 
in the bone development [36]. BMP signaling is initiated through the interaction 
of BMPs with the BMP-receptors (type I and type II). This binding stimulates the 
Figure 1. 
Wnt/β-catenin (canonical) signaling pathway in the osteoblasts. [A] In the absence of Wnt protein, the 
degradation complex Axin, GSK-3β and APC protein phosphorylates the β-catenin and results in the 
ubiquitin-mediated degradation of β-catenin. This turns off the transcription machinery for the osteogenic 
genes and hence transcription for the genes involved in osteogenic differentiation is hampered resulting in 
defective bone formation. [B] Wnt ligand interacts with the receptor complex of Fz and LRP that restricted 
the action of Axin, GSK-3β, and APC protein and hence permitted the transport of β-catenin to the nucleus. 
β-catenin combines with LEF/TCF transcription factors in the nucleus, thereby potentiating the transcription 
for the osteogenic genes.
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process of phosphorylation in the receptors that leads to recruitment and activation 
of Smad proteins, i.e., Smad 1, 5, 8 and Smad4. Smad proteins act as transcriptional 
regulators in the nucleus and ultimately induce the expression of the genes respon-
sible for osteoblastogenesis (Figure 2) [37, 38]. There are a total of 14 members in 
the BMP family, out of which BMP-2,4,5,6,7 and 9 are reported to have high bone 
formation ability [37].
4.3 RANKL mediated signaling
RANKL-based pathway is an essential signaling cascade for the osteoclast 
differentiation. RANKL binds to its receptor RANK (present on the osteoclast 
precursors) and recruits TNF receptor-associated factor (TRAF) adaptor pro-
teins to the conserved TRAF domain present at the cytoplasmic domain of the 
RANK [39, 40]. TRAF transduces the signal to downstream proteins viz. nuclear 
factor kappa B (NF-κB), extracellular signal-regulated kinase (ERK), c-Jun 
N-terminal kinase (JNK), and Nuclear Factor Of Activated T Cells 1 (NFATc1)
(Figure 3) [41, 42]. NF-κB is an important regulator for the osteoclast differen-
tiation. It is mainly responsible for the inflammation-based osteolysis and bone 
resorption [43].
Figure 2. 
Bmp-Smad signaling pathway in the osteoblasts. BMP ligand binds to receptor complex viz. type I (BMPRI) 
and type II receptor (BMPRII). Type II receptor which is a serine/threonine kinase in nature phosphorylates 
and stimulates type I receptor. Upon activation, type I receptor causes phosphorylation of the downstream 
proteins—receptor activated Smads (R-Smads), Smad 1/5/8. Further, R-Smads complexes with co-Smad, 
Smad4 and hence the complex transports to the nucleus. In the nucleus, Smad complex interacts with 
coactivators and finally results in the transcription of osteogenic gene viz. Runx2. Runx2 is a master 
transcription factor for the bone development. It aids in the differentiation of mesenchymal stem cells (MSC) to 
the osteogenic lineage.
Bone Regeneration
6
5. Osteoporosis
Osteoporosis is regarded as a silent bone disorder. Though it is silent and 
associated with least symptoms, it seeks the most attention. It is reported that 
osteoporosis targets every third woman and every fifth man beyond 50 years of 
their ages [44]. Osteoporosis is a pathological condition in which bone mineral 
density is severely diminished with weakened bone microarchitecture [45]. Bones at 
the areas specific to hip, wrist and spine are highly vulnerable for the osteoporotic 
fractures. The occurrence ratio in female to male for the osteoporosis is 1:6 with 61% 
of fractures befalling in the women [46]. Besides, postmenopausal women have 
a greater tendency towards osteoporosis [47]. It is predicted that there would be 
around 6 million victims having osteoporosis by the year 2050 [48]. Osteoporosis is 
categorized into two major types mentioned as follows:
5.1 Primary osteoporosis
Primary osteoporosis is the most usual type of osteoporosis. It has two sub-
categories: Type-I osteoporosis/postmenopausal osteoporosis, is a well-recognized 
bone issue in the postmenopausal women that is chiefly instigated by estrogen 
deficit due to menopause, while type-II osteoporosis/age-related osteoporosis is 
mainly caused as a result of aging in women and men both [49]. In Type-I primary 
Figure 3. 
RANKL-RANK signaling pathway in the osteoclasts. RANKL (present on the surface of osteoblasts) 
interacts with RANK receptor (on the surface of osteoclasts). RANK does not possess any kinase activity and 
hence recruits TRAF proteins to the cytoplasmic region of the receptor. This further transduces the signal to 
downstream components and activates. (1) TAK1 (member of mitogen activated kinase family, MAPK), 
promotes the ERK dependent activation of NFATc1. (2) NFK-β, after the phosphorylation based degradation 
of inhibitor of NFK-β (IKβ). (3) Other downstream proteins viz. JNK that leads to transcriptional activation 
of NFATc1 and additional factors resulting in the osteoclastogenesis.
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osteoporosis, bone loss hastens in the first 5 years of menopause and then slowly 
becomes constant. Estrogen executes the fundamental role in the bone develop-
ment. It stimulates pro-collagen synthesis in the osteoblasts while acting against the 
bone resorbing cytokines [50, 51]. Estrogen is also capable of supporting osteoblast 
differentiation [52]. Moreover, estrogen deficiency induces the production of reac-
tive oxygen species that results in increased osteoclast differentiation [53]. Thus, a 
shortage of estrogen after menopause is one prime cause of osteoporosis majorly in 
women. In the case of type II primary osteoporosis, age is the main cause that leads 
to fractures. With growing age, availability of minerals decreases, oxidants produc-
tion increases while the body becomes less active and does not absorb calcium and 
vitamin D efficiently that overall thins out the density of bone and reduces the 
strength [54].
5.2 Secondary osteoporosis
Bone disorders which are secondary impediments of other health-related 
issues, e.g., adverse effects of drugs interventions, fluctuations in the cycle 
of physical activities, etc. are acknowledged under the category of secondary 
Osteoporosis [49]. Glucocorticosteroids and anticonvulsant-based interventions 
are majorly reported in the cases of secondary osteoporosis [55]. Several other 
disorders, e.g., endocrinopathies, which have the tendency to reduce the bone mass 
and interfere with normal bone formation, are also capable of inducing secondary 
osteoporosis. This form of osteoporosis is found in both pre/post- menopausal 
women and men [55].
6. Current therapeutic measures for osteoporosis
With recent advances in technology and knowledge, many therapeutic strategies 
are available for the management of osteoporosis (Table 1). Broadly, treatment 
measures against osteoporosis are classified under two classes: anti-resorptive and 
anabolic. Anti-resorptive agents work to reduce the rate of bone dissolution while 
anabolic agents attempt to boost bone formation and development.
Drug Administration 
dose of the drug
Mechanism/effect Harmful effects
Anti-resorptive strategies
1. Bisphosphonates
Alendronate 5 mg, 10 mg Inhibits osteoclastogenesis 
by binding to minerals of 
the bone matrix
Severe joint and bone pain, 
serious allergic reactions, 
and osteonecrosis
Zoledronic acid 5 mg/ml Diminishes osteoclast 
mediated bone disruption, 
also treats hypercalcemic 
conditions
Kidney-related issues, 
seizure, intense dizziness, 
and trouble while breathing
2. Estrogen modulators
Raloxifene 60 mg Mimics estrogen like 
effects in the bone 
that decreases bone 
resorption and enhances 
bone density
Risk of breast cancer, 
venous thromboembolism, 
and leg cramps
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7. New therapeutic drug targets for osteoporosis
Apart from tremendous progress in the therapeutic measures currently avail-
able for the check of osteoporosis, the disease still lacks complete eradication 
and immediate effective relief. The side effects, e.g., in bisphosphonate-based 
treatment, adverse effects like femoral fractures and jaw osteonecrosis, etc. are 
often observed. Moreover, instances of osteosarcoma are also reported in the 
anabolic therapies like parathyroid infusions [56, 58]. Hence, the hunt for the novel 
drugs that are specific in action is still continued. In the past few years, promis-
ing research on the topics related to functional genomics and system biology has 
emerged as a powerful remedial tool. Within this regard, RNAi (RNA interference) 
can serve as a new approach of therapeutics in combating bone associated injuries. 
miRNA-based gene antagonism is one such influential arena in the RNAi technol-
ogy. miRNAs can interact well with genes or proteins involved in the process of 
osteogenic differentiation and mineralization.
7.1 MicroRNAs (miRNAs)
miRNAs, a category of small non-coding RNAs, are basically 21–23 nucleotides 
in length. They regulate the gene expression by interacting and degrading the 
complementary mRNA counterparts. Additionally, they also control the expression 
at the protein level via the mode of translational repression of the selected proteins. 
For the suppression of gene, miRNAs mediate mRNA degradation, mRNA decay, 
insulation in P bodies and mRNA deadenylation [59]. At the protein level, miRNAs 
act via inhibiting the initiation or elongation steps of the translation. miRNA 
might also cause ribosome drops and degradation of the nascent protein chain [59].
miRNAs were discovered in the year of 1990 as regulators of gene expression for the 
Drug Administration 
dose of the drug
Mechanism/effect Harmful effects
3. RANKL antagonist
Denosumab 60 mg/ml It is a human monoclonal 
antibody against RANKL 
that prevents the 
formation and maturation 
of osteoclasts
Shortness of breathing 
cycle, warm skin with pus, 
pain while urinating, and 
night sweats
Anabolic strategies
1. Parathyroid hormone (PTH)
Teriparatide 250 mcg/ml It is a recombinant part of 
PTH, that stimulates the 
osteoblastogenesis with 
augmented bone mineral 
density
Heartbeat rate is increased, 
severe dizziness, allergies, 
itching and swelling of 
face, tongue, faintness, and 
osteosarcoma
Abaloparatide 2000 mcg/ml Same as Teriparatide Hypercalciuria, palpitations, 
and spinning sensation
2. Calcitonin 200 IU/ml Encourages bone 
formation, reduces calcium 
levels in the plasma, 
increases net bone mass
Light-headed sensation, 
flushing, nausea, and 
vomiting
Table 1. 
Different anti-osteoporotic therapeutic measures currently available in the market [56, 57].
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developmental processes in the Caenorhabditis elegans [60]. Interestingly, it has 
been stated that miRNA targets one-third of the genes in the human genome [61].
miRNAs are also found in extracellular fluids apart from the cells. Further, they 
are regarded as highly conserved elements among plant and animal kingdoms. In 
the context of nomenclature for the miRNAs, the preface “miR” is succeeded by a 
number that represents the order of naming, i.e. among miR-150 and miR-180, 150 
represents the fact that it is discovered before 180 was found and named [62].
7.2 Biogenesis of miRNA
The miRNA synthesis can be briefly summarized in the following points 
(Figure 4) [63]:
a. The miRNAs genes are generally transcribed by RNA Polymerase II as pri-
miRNA (primary-miRNA) in the animals.
b. A pri-miRNA may encompass one to seven miRNA precursors.
c. Enzymes Drosha and Pasha present in a microprocessor complex cleave the 
long pri-miRNA to shorter pre-miRNA with 2 nucleotide overhangs at 3′ end 
and 5′ phosphates.
d. Finally, a nucleocytoplasmic shuttle protein viz. exportin translocates the 
 pre-miRNA to the cytoplasm.
Figure 4. 
Synthesis pathway for the miRNA. miRNA gene is synthesized by RNA polymerase II in the form of a primary 
transcript (Pri-miRNA). Pri-miRNA is acted upon by microprocessor complex (Drosha and Pasha) resulting 
in the formation of pre-miRNA. From the nucleus, pre-miRNA is transported to the cytoplasm by the shuttle 
protein exportin. In the cytoplasm, dicer targets the pre-miRNA and splices it to miRNA-miRNA duplex. The 
dicer cleavage is linked with the unwinding of the duplex and only one strand is selected to be incorporated into 
the RISC complex. In the RISC complex, miRNA executes its action either on mRNA via mRNA degradation or 
at the protein level by translational repression.
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e. RNase III enzyme called Dicer slices the pre-miRNA into miRNA-miRNA 
duplex in the cytoplasm.
f. The Dicer mediated cleavage is usually associated with the unwinding of 
miRNA duplex wherein one miRNA strand (guide strand) is selected to be 
incorporated in the RISC (RNA induced silencing complex), and the other 
miRNA strand (passenger strand) is frequently degraded. The RISC contains 
Dicer, miRNA, argonaute and other accessory proteins.
g. Argonaute proteins generally interact with the mature miRNA and prepare it in 
the correct orientation for the subsequent binding with mRNA.
h. Perfect base pairing between the miRNA and cognate mRNA leads to degrada-
tion of the target mRNA while imperfect or partial complementarity usually 
results in the suppression at the protein level.
8. miRNA regulation in osteoblast proliferation
Most often, miRNA binds to 3′UTR regions of the genes and executes its action. 
miRNAs are generally regarded as post-transcriptional regulators that check the 
process of proliferation, apoptosis, differentiation and development [64]. Several 
miRNAs are documented to regulate the process of osteogenic proliferation, such as 
excessive expression of miR-221 and miR-215 in the mouse osteoblast cells encour-
ages the proliferative capacity of the cells [65, 66]. Likewise, downregulation of 
miR-185 results in the declined osteoblast proliferation [67]. Besides, increased 
expression of miR-495 in osteoblasts results in diminished proliferation and stimu-
lated apoptosis in the cells [68].
9. miRNA regulation in osteoblast differentiation
Differentiation of the osteoblast cells is an essential facet for the development 
of the adult skeleton. Most importantly, miRNAs have great potential to act against 
miRNA Target gene Targeted signaling pathway Reference
miR-433-3p DKK1 Wnt/β-catenin [69]
miR-208a-3p ACVR1 BMP [70]
miR-1187 BMPR2 BMP2 [71]
miR-29a Histone deacetylase 4 β-catenin [72]
miR-590-5p Smad7 BMP-Smad-Runx2 [73]
miR-450b BMP-3 BMP [74]
miR-135 Smad5 BMP-Smad [75]
miR-34c Notch1 Delta-Notch [76]
miR-224 Smad4 BMP-Smad [77]
miR-21 HIF-1α PTEN/PI3K/Akt [78]
Table 2. 
Role of miRNAs in the osteogenic differentiation by acting on various components in the bone signaling 
pathways.
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or in favor of the genes that are involved in the process of bone differentiation 
(Table 2). miRNA usually targets genes that are participating in the osteo-signaling 
resulting in the bone differentiation.
10. miRNA regulation in bone resorption
miRNAs not only regulates the osteoblastogenesis but also sustains the bone 
disruptive processes by acting on the genes or proteins partaking in the signal-
ing pathways that are functional inside the osteoclast (Table 3). Understanding 
the miRNA mediated regulation of osteoclastic differentiation will highlight the 
mechanism behind the differentiation process for the osteoclasts in the bone [84]. 
Initiating signal (binding of RANKL to the receptors) stimulates various down-
stream pathways (PI3K, NFK-β, MAPK) that on activation of distinct transcription 
factors (c-Fos, NFATc1, PU.1) control the osteoclast differentiation [84].
11. miRNAs as therapeutics
Both the overexpression and inhibition of miRNA can be exploited for the devel-
opment of potential therapeutics. miRNA sponges, Anti-miRNAs and miRNA masks 
are few strategies for the suppression of intracellular miRNAs. Anti-miRNAs are the 
miRNA inhibitors which are constructed as complementary to miRNA sequences. 
They prohibit the binding of miRNAs to the mRNA targets and relieve the gene sup-
pression phenotype. Anti-miRNAs are specific in action as they are custom synthe-
sized as entirely complementary to naturally existing miRNAs [85]. While, delivery 
of miRNA is achieved with the help of miRNA mimics, that imitates the sequence and 
action of miRNAs in the in vitro or in vivo systems. Furthermore, miRNA work as 
both oncogenes and tumor suppressors, thus contributes to the pathogenesis of sev-
eral cancerous diseases. MiR-21 founds to be highly upregulated during breast tumors 
while the levels of miR-196a are significantly increased in the pancreatic cancers 
[86, 87]. Role of miRNAs is also evidently noticed in many other diseases viz. liver 
diseases, cardiac dysfunctions, renal failures, neurodegenerative diseases, etc. [88].
miRNA Target Effect Reference
miR-503 RANK Represses osteoclast formation in PBMC [79]
miR-141 Calcr Suppresses osteoclast differentiation, increases 
bone mineral density
[80]
miR-29a RANKL and 
CXCL12
Decreases osteoclast formation and controls 
osteoporosis
[81]
miR-124 Nfatc1 Represses osteoclast differentiation [82]
miR-155 MITF Suppression of the osteoclastogenesis [83]
miR-21 FasL PDCD4 Hinders the apoptosis of osteoclasts [84]
miR-148a MAFB Encourages osteoclasts development [84]
miR-125a TRAF6 Restricts the formation of osteoclasts [84]
PBMC, peripheral blood mononuclear cells; Calcr, calcitonin receptor; CXCL12, C-X-C motif chemokine 12; MITF, 
microphthalmia-associated transcription factor; PDCD4, programmed cell death protein 4; MAFB, MAF BZIP 
transcription factor B.
Table 3. 
Representation of a few examples where miRNAs have played a vital role in the bone resorption.
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11.1 miRNA-based therapeutics in osteoporosis
During osteoporosis, the balance between bone formation and bone elimi-
nation is disrupted [89]. Bone dissolution dominates the bone formation and 
thereby results in the weakened matrix and compromised bone strength. miRNA 
attempts to correct the imbalance and preserves the bone homeostasis towards 
bone development during the process of remodeling. miRNAs suppress the genes 
or proteins involved in the biological signaling pathway and hence aid the pathway 
to proceed in accurate and normal fashion [90]. This normalization of the pathway 
further facilitates the optimum differentiation of the mesenchymal stem cells to 
the osteoblastic lineage. In the past few years, several investigations have emerged 
which conveys the role of miRNAs in the prognosis and treatment of osteoporosis 
(Table 4).
12. miRNAs as biomarkers
Circulatory miRNAs that are available in the extracellular fluids, e.g., serum, 
plasma, tears, etc., are potent to be utilized as essential biomarkers in the bone 
associated issues. Circulatory miRNAs are generally secreted in the form of exo-
somes or microvesicles, and thus they are guarded against the action of nucleases. 
Blood plasma miRNAs have been reported as biomarkers in the diagnosis of 
Non-small-cell lung carcinoma stage I and II [98]. Further, miRNAs present in the 
human saliva have also been described as biomarkers during the menstrual cycle in 
women [99]. Serum biomarkers from the osteoporotic patients representing precise 
miRNA Treatment: gain/
loss of function 
of the miRNA
Disease 
(osteoporotic 
models)
Effect Reference
miR-148a Loss of 
function using 
AntagomiR-148a
OVX mice Diminished bone resorption 
and enhanced bone mass
[91]
miR-103a AntagomiR-103a Hindlimb unloaded 
mice
Neutralized the loss of 
bone, better bone mass
[92]
miR-31a-5p AnatgomiR-31a-5p Aged rats (Injections 
at the bone marrow 
cavity in the femur)
Reduced osteoclastogenesis 
and increased 
osteoblastogenesis
[93]
miR-1187 Anti-miR-1187 Ovariectomized 
BALB/c mice
Improved bone 
microarchitecture
[71]
miR-214 miR-214 sponges OVX rat with 
femoral metaphysis 
critical size defect
Healing of critical size 
defect
[94]
miR-451a Gain of function 
using miR-451a 
mimic
OVX mice Improved bone strength 
and increased bone 
mineralization
[95]
miR-7b miR-7b mimic OVX mice Augmented bone 
vascularization and bone 
volume
[96]
miR-199a-5p miR-199a-5p 
agomiR
Sprague-Dawley rats Better bone regeneration in 
the tibia-defects
[97]
Table 4. 
Representation of the current studies where miRNAs are used as therapeutics in the treatment of osteoporosis.
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pathological condition may serve as crucial diagnostic tools in the clinical practice. 
Studies in the past years have depicted the relevance of extracellular miRNAs in the 
plasma or serum samples from the osteoporotic patients relative to healthy controls. 
miRNAs viz. hsa-miR-122-5p and hsa-miR-4516 have been documented as putative 
markers in the diagnosis of osteoporosis [100]. Similarly, in another study, miR-21, 
miR-23a, miR-24, miR-93 and miR-100 are highly upregulated in the serum of 
osteoporotic patients [101]. Even in the investigation of postmenopausal osteopo-
rosis, miR-422 has been regarded as an essential biomarker gene [102]. Based on 
several validated studies, it can precisely be concluded that miRNAs may act as 
useful potential biomarkers in the examination of distinct medical implications, 
including osteoporosis.
13. miRNA as potential new generation drugs
miRNAs are emerging as promising drugs in the pharmaceutical market. They are 
endogenous and hence associated with less harmful events for the body. Employing 
miRNAs as therapeutic targets have one key benefit that nucleotide content of the 
miRNAs can be easily modified by chemicals for the improved pharmacokinetics 
and pharmacodynamics of the potential miRNA-based drugs. Besides, miRNA has 
the capability of targeting multiple genes at a time. Moreover, nowadays chemical 
locked nucleic acid modifications are present for addressing the issues related to the 
susceptibility of miRNAs to the intracellular nucleases. Likewise, phosphorothioate 
alteration is another way of improving the efficacy of miRNAs in the in vivo systems 
[103]. Recently FDA approved drug, Onpattro against polyneuropathy marks the 
foundation of RNAi technology-based medicines in the commercial space. Table 5 
describes a few miRNA-based therapeutic compounds that are on the success path of 
drug development at the preclinical and clinical stages [104, 105].
14. Conclusion
In healthy body conditions, miRNAs are expected to assist in the maintenance of 
a regulated balance between the osteoblast-based bone-forming activity and osteo-
clast dependent bone-resorbing activity. This balance is dependent on the action of 
miRNAs on the biochemical signaling pathways operating inside the bone. While, 
during pathologies, the aberrant expression of the miRNAs due to misregulated 
miRNA Drug format Disease Stage of clinical trial
miR-122 miR-122 Antisense 
inhibitor
HCV Phase II
RG-012 Anti-miR-21 Alport syndrome At the initiating stage of the 
phase II trial
miR-3 Mimic replacement Cancers including 
hepatocellular
Phase I
Let-7 Mimic Replacement Cancer Preclinical
miR-103/105 miR-inhibitor Insulin resistance Preclinical
miR-10b miR-10b inhibitor Glioblastoma Preclinical
Table 5. 
List of few miRNAs which are presently in the development.
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bone signaling comes into existence. The upregulated or downregulated miRNAs 
during osteoporosis may serve as biomarkers or gene therapy targets respectively 
in the management of bone associated injuries including osteoporosis. As miRNAs 
are expressed in tissue specific manner, therefore miRNA-based biomarkers can 
differentiate between variable bone-related medical conditions, i.e. defects in bone 
fragility, reduction in bone mass density, osteoclast malfunctioning, etc. In addi-
tion, miRNA bears pleiotropic nature that favors controlling the diseases that have 
no efficient treatments as yet. Advances in the number of reports regarding miRNA 
therapeutics in osteoporosis display massive translational utility of miRNAs in the 
clinical practices. miRNAs are naturally occurring and expected to pose nil or few 
side effects to the body. The access of the first miRNA mediated therapy against 
hepatitis C virus infection (HCV) in the clinical phase has fulfilled the hopes for the 
success of miRNAs as potential therapeutic agents in the drug market. To conclude, 
miRNAs can undoubtedly be addressed as new generation drugs for the efficient 
and effective check of osteoporosis.
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